Estimating the cost effectiveness of ramipril used for specific clinical indications: Comparing the outcomes in four clinical trials with a common economic model

American Journal of Cardiovascular Drugs

Volumn 7, Issue 6, 2007, Pages 441-448

  Grover, Steven A ^a,b   Coupal, Louis ^a   Lowensteyn, Ilka ^a  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

RAMIPRIL;

ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; FEMALE; HEALTH CARE COST; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROBABILITY; QUALITY OF LIFE; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 37149048092     PISSN: 11753277     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129784-200707060-00007     Document Type: Article

References (38)

1. Lamy A, Yusuf S, Pogue J, et al., on behalf of the HOPE Investigators. Cost implications of the use of ramipril in high-risk patients based on the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation 2003; 107: 960-5
2. Carroll CA, Coen MM, Rymer MM. Assessment of the effect of ramipril therapy on direct health care costs for first and recurrent strokes in high-risk cardiovascular patients using data from the Heart Outcomes Prevention Evaluation (HOPE) Study. Clin Ther 2003; 25: 1248-61
3. Carroll CA, Coen MM, Piepho RW. Economic impact of ramipril on hospitalization of high-risk cardiovascular patients. Ann Pharmacother 2003; 37: 327-31
4. Malik IS, Bhatia VK, Kooner JS. Cost effectiveness of ramipril treatment for cardiovascular risk reduction. Heart 2001; 85: 539-43
5. Beard SM, Gaffney L, Backhouse ME. An economic evaluation of ramipril in the treatment of patients at high risk for cardiovascular events due to diabetes mellitus. J Med Econ 2001; 4: 199-205
6. Björholt I, Andersson FL, Kahan T, et al. The cost-effectiveness of ramipril in the treatment of patients at high risk of cardiovascular events: a Swedish sub-study to the HOPE study. J Intern Med 2002; 251: 508-17
7. Erhardt L, Ball S, Andersson F, et al. Cost effectiveness in the treatment of heart failure with ramipril: a Swedish substudy of the AIRE study. Pharmacoeconomics 1997; 2: 256-66
8. Hart WM, Rubio-Terres C, Pajuelo F, et al. Cost-effectiveness of the treatment of heart failure with ramipril: a Spanish analysis of the AIRE study. Eur J Heart Fail 2002; 4: 553-8
9. Schädlich PK, Huppertz E, Brecht JG. Cost-effectiveness analysis of ramipril in heart failure after myocardial infarction: economic evaluation of the acute infarction ramipril efficacy (AIRE) study for Germany from the perspective of statutory health insurance. Pharmacoeconomics 1998; 14: 653-69
10. Schädlich PK, Brecht JG, Rangoonwala B, et al. Cost effectiveness of ramipril in patients at high risk for cardiovascular events. Pharmacoeconomics 2004; 22: 955-73
11. Ruggenenti P, Pagano E, Tammuzzo L, et al. Ramipril prolongs life and is cost effective in chronic proteinuric nephropathies. Kidney Internat 2004; 59: 286-94
12. Schädlich PK, Brecht JG, Brunetti M, et al. Cost effectiveness of ramipril in patients with non-diabetic nephropathy and hypertension. Pharmacoeconomics 2001; 19: 497-512
13. Munter P, He J, Hamm L, et al. Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol 2002; 13: 745-53
14. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-53
15. Heart Outcomes Prevention Evaluation. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-9
16. Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effects of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821-8
17. GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997; 349: 1857-63
18. Grover SA, Paquet S, Levinton C, et al. Estimating the benefits of modifying risk factors of cardiovascular disease: a comparison of primary vs secondary prevention. Arch Intern Med 1998; 158: 655-62
19. Grover SA, Coupal L, Paquet S, et al. Cost-effectiveness of 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitors in the secondary prevention of cardiovascular disease: forecasting the incremental benefits of preventing coronary and cerebrovascular events. Arch Intern Med 1999; 159: 593-600
20. Heiss G, Tamir I, Davis CE, et al. Lipoprotein-cholesterol distributions in selected North American populations: the Lipid Research Clinics Program Prevalence Study. Circulation 1980; 61: 302-15
21. Grover SA, Coupal L, Zowall H, et al. Cost-effectiveness of treating hyperlipidemia in the presence of diabetes: who should be treated? Circulation 2000; 102: 722-7
22. Grover SA, Coupal L, Gilmore N, et al. Impact of dyslipidemia associated with highly active antiretroviral therapy (HAART) on cardiovascular risk and life expectancy. Am J Cardiol 2005; 95: 586-91
23. Grover SA, Coupal L, Kaouache M, et al. Preventing cardiovascular disease among Canadians: what are the potential benefits of treating hypertension or dyslipidemia. Can J Cardiol 2007; 23: 467-73
24. Grover SA, Coupal L, Zowall H, et al. How cost-effective is the treatment of dyslipidemia in patients with diabetes but without cardiovascular disease? Diabetes Care 2001; 24: 45-50
25. Grover SA, Coupal L, Lowensteyn I. Determining the cost-effectiveness of preventing cardiovascular disease: are estimates calculated over the duration of a clinical trial adequate? Can J Cardiol. In press
26. Canadian Organ Replacement Register (CORR) Canadian Institute for Health Information. Characteristics of incident ESRD patients, Canada, 2000 [online]. Available from URL: http://secure.cihi.ca/cihiweb/en/reports_corrin- sites_sep2002_national_t1_e.html [Accessed 2007 May 1]
27. Fryback DG, Dasbach EJ, Klein R, et al. The Beaver Dam health outcomes study: initial catalog of health-state quality factors. Med Decis Making 1993; 13: 89-102
28. Churchill DN, Torrance GW, Taylor DW. Measurement of quality of life in end-stage renal disease: the time trade-off approach. Clin Invest Med 1987; 10: 14-20
29. Resource intensity weights: summary of methodology, 1996/97. Ottawa (ON): Canadian Institute for Health Information, 1996
30. Régie de l'assurance maladie du Québec. Manuel des Médecins Spécialistes RAMQ. Quebec City (QC): Régie de l'assurance maladie du Québec, 1996
31. Ontario Ministry of Health. Schedule of benefits: physician services, 1992. Toronto (ON): Ontario Ministry of Health, 1992
32. Statistics Canada. CANSIM Matrix 9440, Series L. Ottawa (QC): Statistics Canada, 2000
33. Statistics Canada. CANSIM Matrix P100200. Ottawa (QC): Statistics Canada, 2000
34. Statistics Canada. CANSIM Matrix L95705. Ottawa (QC): Statistics Canada, 2000
35. Goeree R, Manalich J, Grootendorst P, et al. Cost analysis of dialysis treatments for end-stage renal disease (ESRD). Clin Invest Med 1995; 18: 455-64
36. Laupacis A, Keown P, Pus N, et al. A study of the quality of life and cost-utility of renal transplantation. Kidney Internat 2006; 501: 235-42
37. IMS Canada. Canadian Compuscript, November 2000. Point-Claire (QC): IMS Canada, 2000
38. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-305